Page 1

SCANDION ONCOLOGY Press Release September 8 , 2021 Scandion Oncology provides a clear path to market for SCO - 101 at today's Capital Markets Day Scandion Oncology A / S , the Cancer Drug Resistance Company , today announced it will provide novel information on its lead candidate drug SCO - 101 and a focused clinical strategy with a clear path to registration at today's Capital Markets Day . The company will also communicate about its pipeline , future business opportunities and give an update from part 1 of the CORIST Phase II study . Data from the CORIST study have triggered an updated focused clinical strategy . Scandion has documented a unique Mode of Action ( MoA ) for SCO - 101 in the CORIST study , where the company shows a significant potentiation of Irinotecan by combining SCO - 101 with FOLFIRI in patients . The combination resulted in a dramatically increased exposure and half - life of SN - 38 ( the active metabolite of Irinotecan ) . The molecular mechanism of action driving the increased exposure has been identified . The Company has filed a patent application on this unique mode of action . Scandion Oncology will become a Phase III company " Our path forward is built on a unique Mode of Action ( MoA ) and we have focused our clinical strategy to provide a clear route to registration and return on investments in RAS wild - type metastatic colorectal cancer . The ultimate outcome is to become a Phase III company as early as in 2023. We further see a huge opportunity for building on this platform knowledge , to broaden the clinical opportunities for SCO - 101 in combination with Irinotecan and maximize business value , " said Bo Rode Hansen , President & CEO . Refocusing from last line mCRC to 2nd line This also means , that Scandion will refocus from last line metastatic colorectal cancer ( mCRC ) to second line of treatment to add significantly more value . To maximize the market potential in second line mCRC , the Company aims to position SCO - 101 in combination with VEGF monoclonal antibodies ( mAbs ) and / or EGFR monoclonal antibodies ( mAbs ) which are used as backbone in 1st and 2nd line of treatment of RAS wild - type mCRC . In preparation for the pivotal study , the company will redesign part 3 of CORIST , which is funded , to include 10 patients as a separate arm that will run in parallel to the 25 patients in CORIST part 2 . CORIST part 3 will evaluate safety of combining SCO - 101 and FOLFIRI with mAbs ( VEGF and / or EGFR ) , pharmacokinetics and be included in the overall efficacy assessment in CORIST Phase II . The company is further planning to open an Investigational New Drug ( IND ) , to allow for inclusion of patients from US clinical sites . Focusing our pipeline on value creation and highest probability of success " We are prioritizing SCO - 101 in combination with Irinotecan over other projects in our pipeline , as we see the most value creation potential for this combination . We will therefore cease investing in less documented MoAs including SCO - 101 in combination with anti - oestrogens and in indications outside of cancer ( antibiotics ) . The implications are that we de - prioritize two of our preclinical projects : EndoRIST and SOM - 001 . In terms of pipeline , we will focus on maximum value creation and highest probability of success . We have defined a clear roadmap for our coming years , " said Bo Rode Hansen . The Capital Markets Day will take place between 9am and 11.30am CET today and will be webcasted live and is accessible at : https://www.lyyti.fi/reg/Capital Markets Day Scandion Oncology 7500 . Scandion Oncology A / S - Symbion Fruebjergvej 3 - DK 2100 Copenhagen - Denmark www.scandiononcology.com - CVR No. 38613391 Page 1 of 2